$30.74
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. The company is headquartered in Watford, Hertfordshire and currently employs 16,988 full-time employees. The firm is focused on the repair, regeneration, and replacement of soft and hard tissue. The firm's segments include Orthopaedics, which includes a range of hip, knee and shoulder implants used to replace diseased, damaged or worn joints, robotics-assisted enabling technologies that empower surgeons, and trauma products used to stabilize severe fractures and correct bone deformities; Sports Medicine & ENT businesses offer advanced products and instruments used to repair or remove soft tissue, and Advanced Wound Management provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds. The firm also owns Integrity Orthopaedics, which is an early stage commercial developer of Tendon Seam, an innovative and disruptive biomechanical RCR system.
Country

GB

CEO

Mr. Deepak Nath

IPO date

1951

Employees

16,988

ISIN

GB0009223206

Key stats

Open

$30.59

Volume

1.40M

Market cap

$9.49B

Prev. close

$30.40

Impl / hst vl

-

Open interest

$0.00

$30.40

Day’s Range

$30.84

$28.56

52W Range

$37.09

Valuation

72
Valuation score
Undervalued
P/E
20.34
P/S
2.06
P/B
2.40
Current ratio
2.57
Debt / Equity
0.52
ROE
11.55%
Gross margin
65.59%
Income growth
13.31%
FCF growth
131.52

May

27

Dividends

The last payment date was May 27, 2026

Div. per Share

$0.48

Div. Yield

1.59%

Payout Ratio

-

Div. Growth YoY

60.67%

Analysts estimates

Consensus rating
Hold

The average rating from top 12 analysts indicates that stock may significantly underperform the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$37.28
The top 19 analysts forecasts that 12-month price may increase by 21.27%, with a low of $32.90 and a high of $44.49
$32.90
Low
$37.28
Avg
$44.49
High
Current price

Earnings

Q4 ‘25 revenue
$3.20B
Q4 ‘25 net income
$332.00M
Revenue
Net income
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply